Adverum Biotechnologies (NASDAQ:ADVM) spotted trading -26.77% off 52-week high price. On the other end, the stock has been noted 204.70% away from the low price over the last 52-weeks. The stock changed -1.20% to recent value of $12.31. The stock transacted 1812108 shares during most recent day however it has an average volume of 1.39M shares. The company has 74.99M of outstanding shares and 71.41M shares were floated in the market.
On Feb. 25, 2020, Adverum Biotechnologies (NASDAQ:ADVM) a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, disclosed that Angela Thedinga has been promoted to chief technology officer. Ms. Thedinga joined Adverum in August 2019 as the company’s vice president of program management and strategy, and will now lead Adverum’s technology and operations organization, including process development, manufacturing, and supply chain management.
I am pleased to congratulate Angela on her role as CTO, who since joining the company has demonstrated executive leadership across the organization and strategic insight, said Leone Patterson, president and chief executive officer of Adverum Biotechnologies. Angela’s deep experience transitioning and expanding viral vector gene therapy manufacturing and analytical capabilities from academic to commercial scale is increasingly important to the growth of our business as we continue the development and potential commercialization of ADVM-022, a novel gene therapy to treat patients with serious ocular diseases.
Before joining Adverum, Ms. Thedinga served as vice president of program management and chief of staff at AveXis, a gene therapy company acquired by Novartis in 2018. Ms. Thedinga was instrumental in developing the early manufacturing strategy which enabled AveXis to transition its early-stage AAV manufacturing process to a scalable commercial manufacturing process. As chief of staff at AveXis, Ms. Thedinga led the company-wide effort for the global simultaneous regulatory submissions and the commercial launch of Zolgensma®, the first systemically delivered AAV gene therapy to receive approval by the U.S. Food and Drug Administration. Earlier in her career, Ms. Thedinga held manufacturing strategy roles of increasing responsibility at Novartis AG and Abbott Laboratories.
Ms. Thedinga earned a Master’s degree in chemical engineering from the Massachusetts Institute of Technology, a Master of Business Administration from the MIT Sloan School of Management, a Master of Public Health from the University of North Carolina at Chapel Hill, and a Bachelor of Science in chemical engineering from the University of Wisconsin. At MIT, Ms. Thedinga was a member of the Leaders for Global Operations program and was named a Siebel Scholar. Its earnings per share (EPS) expected to touch remained -12.40% for this year.
According to the most recent quarter its current ratio was 9.4 that represents company’s ability to meet its current financial obligations. The price moved ahead of -5.68% from the mean of 20 days, 2.66% from mean of 50 days SMA and performed 17.29% from mean of 200 days price. Company’s performance for the week was -17.08%, 13.88% for month and YTD performance remained 6.86%.